April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Long Term Follow- Up in Patients With Choroidal Neovascularization Associated With Pathologic Myopia Treated With Intravitreal Injection of Bevacizumab
Author Affiliations & Notes
  • E. Peiretti
    Ophthalmology, Univerity Eye Clinic of Cagliari, Cagliari, Italy
  • M. Vinci
    Ophthalmology, Univerity Eye Clinic of Cagliari, Cagliari, Italy
  • M. Fossarello
    Ophthalmology, Univerity Eye Clinic of Cagliari, Cagliari, Italy
  • Footnotes
    Commercial Relationships  E. Peiretti, None; M. Vinci, None; M. Fossarello, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2202. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Peiretti, M. Vinci, M. Fossarello; Long Term Follow- Up in Patients With Choroidal Neovascularization Associated With Pathologic Myopia Treated With Intravitreal Injection of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2202.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to evaluate in a monocenter, consecutive,non randomized interventional case series of 21 eyes the long-term efficacy of intravitreal injection of bevacizumab (Avastin) in patients with choroidal neovascularization (CNV) associated with pathologic myopia (PM).

Methods: : retrospective study on a group of 21 eyes of 21 patients (mean age 59 yrs) with CNV associated with PM (mean - 12 diopters ,+/- -5) were treated with at least 2 intravitreal injections of 1.25 mg/0.05 ml bevacizumab. Four patients were treated with verteporfin PDT before bevacizumab injection. Patients underwent a complete ophthalmological examination at baseline and at follow-up visits, including Snellen visual acuity (VA) testing, optical coherence tomography (OCT), fluorescein (FA) and indocyanine green (ICG) retinal angiography. The median follow-up was 30,9 months (DS 6,15) in a range between 25 and 42 months. The patients who showed recurrence of the lesion, as assessed by FA, OCT and visual symptoms were retreated for a maximum of 15 injections. No side effects were observed in our series.

Results: : pre-treatment mean best corrected (BC) VA was logMAR 0,67± 0,43. At 1 year follow-up, mean BCVA was logMAR 0,51 ±0,39 and at the end of follow up the VA was logMAR 0,57±0,45. At minimum follow up of 25 months, 61,9% (13eyes) of patients demonstrated an improvement of VA from 1 to 3 Snellen lines. 23,8% (5 eyes)of patients showed stabilizations of VA acuity with minimal amount of subretinal fluid, as assessed by OCT examination and the remaining patients 14,3%(3 patients). No significant ocular or systemic side effects were observed in our patients after bevacizumab injection.

Conclusions: : on the basis of our preliminary data, intravitreal injection of bevacizumab should be considered as effective treatment for patients with CNV associated with PM.

Keywords: choroid: neovascularization • myopia • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×